Hemosol Inc. announced that it has completed its publicoffering of 3.2 million shares of common stock at C$11(U.S.$8.73) per share. The shares will be listed on the TorontoStock Exchange under the symbol HDL.

The Toronto blood substitute company grossed C$35 million(U.S. $27.8 million) from the offering, which was underwrittenby Gordon Capital Corp., Midland Walwyn Capital Inc., WoodGundy Inc. and RBC Dominion Securities Inc. The underwritershave the option to purchase 318,150 additional common sharesto cover overallotments.

(c) 1997 American Health Consultants. All rights reserved.

No Comments